New York Life Investment Management LLC purchased a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 9,019 shares of the company’s stock, valued at approximately $1,271,000.
Other institutional investors also recently made changes to their positions in the company. BlackRock Inc. bought a new stake in Protagonist Therapeutics in the second quarter worth $1,263,535,000. Johnson & Johnson bought a new position in shares of Protagonist Therapeutics during the second quarter valued at about $300,220,852. Jupiter Topco LLC purchased a new position in shares of Protagonist Therapeutics in the second quarter worth about $261,039,000. Bank of America Corp DE bought a new position in Protagonist Therapeutics during the 2nd quarter worth approximately $162,357,000. Finally, ADAR1 Capital Management LLC bought a new position in Protagonist Therapeutics during the 2nd quarter worth approximately $117,783,000. Hedge funds and other institutional investors own 98.63% of the company’s stock.
Insider Buying and Selling
In other news, CFO Asif Ali sold 58,629 shares of Protagonist Therapeutics stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $141.78, for a total value of $8,312,419.62. Following the completion of the transaction, the chief financial officer owned 59,003 shares of the company’s stock, valued at $8,365,445.34. The trade was a 49.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 63,548 shares of the company’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $146.18, for a total transaction of $9,289,446.64. Following the completion of the transaction, the chief executive officer owned 522,968 shares in the company, valued at approximately $76,447,462.24. The trade was a 10.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 183,629 shares of company stock valued at $26,552,987. 5.19% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
PTGX has been the topic of several recent analyst reports. UBS Group restated a “buy” rating on shares of Protagonist Therapeutics in a report on Tuesday, November 3rd. TD Cowen boosted their price objective on shares of Protagonist Therapeutics from $155.00 to $160.00 and gave the company a “buy” rating in a research report on Wednesday, October 21st. Truist Financial raised their target price on Protagonist Therapeutics from $145.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. BMO Capital Markets upped their price target on Protagonist Therapeutics from $178.00 to $190.00 and gave the company an “outperform” rating in a research report on Tuesday, September 1st. Finally, Wolfe Research reissued an “outperform” rating on shares of Protagonist Therapeutics in a research note on Monday, August 31st. One analyst has rated the stock with a Strong Buy rating and sixteen have assigned a Buy rating to the company. Based on data from MarketBeat.com, Protagonist Therapeutics presently has an average rating of “Buy” and a consensus target price of $166.67.
View Our Latest Research Report on Protagonist Therapeutics
Protagonist Therapeutics Price Performance
Shares of PTGX stock opened at $130.95 on Monday. The business’s fifty day moving average is $140.30 and its 200 day moving average is $119.11. The stock has a market cap of $8.55 billion, a price-to-earnings ratio of 27.74 and a beta of 1.21. Protagonist Therapeutics, Inc. has a twelve month low of $77.00 and a twelve month high of $160.81.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $3.07 EPS for the quarter, beating analysts’ consensus estimates of $2.50 by $0.57. Protagonist Therapeutics had a net margin of 62.04% and a return on equity of 42.83%. The firm had revenue of $274.41 million for the quarter, compared to analysts’ expectations of $238.49 million. Equities research analysts expect that Protagonist Therapeutics, Inc. will post 5.52 earnings per share for the current fiscal year.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.
See Also
- Five stocks we like better than Protagonist Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report).
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
